Explore a selection of our essential drug information below, or:
Identification
- Summary
Bromopride is a substituted benzamide, closely related to metoclopramide, used as an antiemetic.
- Generic Name
- Bromopride
- DrugBank Accession Number
- DB09018
- Background
Bromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Bromopride (DB09018)
- Weight
- Average: 344.247
Monoisotopic: 343.08953961 - Chemical Formula
- C14H22BrN3O2
- Synonyms
- 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
- Bromoprid
- Bromoprida
- Bromopride
- Bromopridum
- External IDs
- VAL 13081
Pharmacology
- Indication
Bromopride in indicated in the treatment of nausea and vomiting, including PONV (post-operative nausea and vomiting), gastroesophageal reflux disease (GERD/GORD), as well as endoscopy preparation and radiographic studies of the GI tract.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Decreased appetite •••••••••••• ••••••• Used in combination to treat Deficiency digestive enzymes Combination Product in combination with: Pancrelipase (DB00085), Dimethicone (DB11074) •••••••••••• ••••••• •••••• Used in combination to treat Flatulence Combination Product in combination with: Dimethicone (DB11074), Pancrelipase (DB00085) •••••••••••• ••••••• •••••• Treatment of Gastrointestinal motility and defaecation conditions •••••••••••• ••••••• Treatment of Gastrointestinal motility and defaecation conditions •••••••••••• ••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AD(2) dopamine receptor antagonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
40%.
- Metabolism
Hepatic.
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Renal, 10-14% as original compound.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareApomorphine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Bromopride. Aripiprazole The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Bromopride. Benzatropine The risk or severity of adverse effects can be increased when Bromopride is combined with Benzatropine. Brexpiprazole The therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Bromopride. Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Bromopride. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Bromopan (UCI) / Digesan (Sanofi) / Emepride / Emoril / Movipride (Merck) / Plamet / Viadil
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ENZYMED®TABLETAS RECUBIERTAS Bromopride (5 mg) + Dimethicone (60 mg) + Pancrelipase (400 mg) Tablet, coated Oral BIOCHEM FARMACEUTICA DE COLOMBIAS.A. 2006-11-10 2021-04-01 Colombia 
Categories
- ATC Codes
- A03FA04 — Bromopride
- Drug Categories
- Acids, Carbocyclic
- Alimentary Tract and Metabolism
- Amides
- Aminobenzoates
- Antiemetics
- Autonomic Agents
- Benzamides and benzamide derivatives
- Benzene Derivatives
- Benzoates
- Central Nervous System Agents
- Chlorobenzoates
- Dopamine Agents
- Dopamine Antagonists
- Dopamine D2 Receptor Antagonists
- Drugs for Functional Gastrointestinal Disorders
- Gastrointestinal Agents
- Hydroxy Acids
- Hydroxybenzoate Ethers
- Hydroxybenzoates
- Neurotransmitter Agents
- para-Aminobenzoates
- Peripheral Nervous System Agents
- Phenols
- Phenyl Ethers
- Propulsives
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminophenyl ethers. These are aromatic compounds that contain a phenol ether, which carries an amine group on the benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenol ethers
- Sub Class
- Aminophenyl ethers
- Direct Parent
- Aminophenyl ethers
- Alternative Parents
- Methoxyanilines / Phenoxy compounds / Methoxybenzenes / Anisoles / 2-bromoanilines / Bromobenzenes / Alkyl aryl ethers / Aryl bromides / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds show 5 more
- Substituents
- 2-bromoaniline / Alkyl aryl ether / Amine / Aminophenyl ether / Aniline or substituted anilines / Anisole / Aromatic homomonocyclic compound / Aryl bromide / Aryl halide / Bromobenzene show 21 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 75473V2YZK
- CAS number
- 4093-35-0
- InChI Key
- GIYAQDDTCWHPPL-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)
- IUPAC Name
- 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
- SMILES
- CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC
References
- Synthesis Reference
U.S. Patents 3,177,252; 3,219,528; and 3,357,978.
- General References
- Not Available
- External Links
- KEGG Drug
- D07101
- PubChem Compound
- 2446
- PubChem Substance
- 310264975
- ChemSpider
- 2352
- BindingDB
- 50247887
- 19768
- ChEBI
- 95304
- ChEMBL
- CHEMBL399510
- ZINC
- ZINC000002038104
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Bromopride
- MSDS
- Download (105 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Dyspepsia 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Oral 4 mg Solution Oral 1 mg Tablet, coated Oral Tablet Oral Pill Tablet, coated Capsule - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US3177252 No 1962-07-17 1982-07-17 US 
US3219528 No 1962-07-17 1982-07-17 US US3357978 No 1964-02-28 1984-02-28 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 134-135 U.S. Patents 3,177,252; 3,219,528; and 3,357,978. - Predicted Properties
Property Value Source Water Solubility 0.241 mg/mL ALOGPS logP 2.36 ALOGPS logP 1.56 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 14.58 Chemaxon pKa (Strongest Basic) 9.04 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 67.59 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 86.34 m3·mol-1 Chemaxon Polarizability 33.92 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 173.18181 predictedDeepCCS 1.0 (2019) [M+H]+ 175.53981 predictedDeepCCS 1.0 (2019) [M+Na]+ 181.63297 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase (PubMed:21645528). Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)
- Specific Function
- dopamine binding
- Gene Name
- DRD2
- Uniprot ID
- P14416
- Uniprot Name
- D(2) dopamine receptor
- Molecular Weight
- 50618.91 Da
References
- Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F: Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004 Feb 15;19(4):379-90. [Article]
Drug created at June 23, 2014 21:53 / Updated at May 27, 2021 02:57